117 related articles for article (PubMed ID: 31634155)
1. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
Diaz CL; Cinar P; Hwang J; Ko AH; Tempero MA
Am J Clin Oncol; 2019 Dec; 42(12):898-902. PubMed ID: 31634155
[TBL] [Abstract][Full Text] [Related]
2. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
3. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Balzano G; Passoni P; Rognone A; Fugazza C; Mazza E; Zerbi A; Di Carlo V; Villa E
Cancer; 2009 Jun; 115(12):2630-9. PubMed ID: 19353729
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
6. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
9. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
12. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Wong D; Ko AH; Hwang J; Venook AP; Bergsland EK; Tempero MA
Pancreas; 2008 Oct; 37(3):269-74. PubMed ID: 18815548
[TBL] [Abstract][Full Text] [Related]
13. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
14. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Preoperative Serum Carbohydrate Antigen 19-9 in Patients With Stage IV Colorectal Cancer.
Ozawa T; Ishihara S; Kawai K; Nozawa H; Yamaguchi H; Kitayama J; Watanabe T
Clin Colorectal Cancer; 2016 Dec; 15(4):e157-e163. PubMed ID: 27245559
[TBL] [Abstract][Full Text] [Related]
16. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
17. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis.
Colloca GA; Venturino A; Guarneri D
Pancreatology; 2020 Sep; 20(6):1189-1194. PubMed ID: 32747196
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
